Single enzyme may be linked to obesity

December 06, 2001

BOSTON - The increased activity of a single enzyme in fat cells may be a common cause of obesity and obesity-linked diseases, including diabetes, according to an animal study conducted by researchers at Beth Israel Deaconess Medical Center and the University of Edinburgh and published in the Dec. 7 issue of Science. The findings could eventually pave the way for future drug development to curb visceral obesity - the "beer belly" fat concentrated in the abdomen.

"Hundreds of studies have led to the conclusion that any fat can be problematic, but it's much, much more dangerous when it's accumulated in the abdomen," notes lead author Jeffrey S. Flier, M.D., an endocrinologist at Beth Israel Deaconess Medical Center and the George C. Reisman Professor of Medicine at Harvard Medical School. "Pound for pound, intra-abdominal fat is much more likely to cause diabetes, heart disease and other diseases that make up the metabolic syndrome."

To identify the molecular mechanism behind the accumulation of the excess abdominal fat, Flier and his colleagues looked at the role of the glucocorticoid hormone cortisol, the "fight or flight" hormone that helps people survive stressful situations. Observations of patients with the endocrine disorder Cushing's syndrome - who have too much cortisol in their blood - had shown that they develop increased intra-abdominal fat as well as other metabolic symptoms. This led Flier to hypothesize that obese patients - who don't typically have increased blood cortisol levels - may be producing increased amounts of cortisol in their fat cells.

To test this hypothesis, Flier and his colleagues studied the enzyme 11beta hydroxysteroid dehydrogenase type 1 (11 beta HSD-1), which has the unique ability to produce cortisol in cells that are not normally associated with cortisol production. This enzyme is known to be present in fat cells.

The researchers created a group of transgenic (Tg) mice that overproduce 11 beta HSD-1 in roughly the same quantities previously found in the fatty tissue of obese humans. As predicted, these mice had increased levels of cortisol in their fat, but not in their blood. The Tg mice were then compared with a group of non-Tg mice. For the first nine weeks of life both groups of mice were fed low-fat diets, and their body weights were indistinguishable. But, after nine weeks, the Tg mice steadily gained weight, and by 15 weeks of age, weighed 16 percent more than the non-Tg mice. The Tg mice were also more sensitive to weight gain when fed a high-fat diet. An external examination of the mice showed prominent weight gain in the abdominal areas of the Tg mice.

Further tests using X-ray absorptiometry to measure fat in the whole body and in the abdominal region showed that fat accumulation in the abdominal region of non-Tg mice on high-fat diets was comparable to that of Tg mice on low-fat diets. The ratio was further exaggerated when Tg mice were fed high-fat diets.

"We were surprised to find that it took only a modest increase in this enzyme to cause the mice to become viscerally obese. The animals also developed diabetes, became resistant to insulin, developed high blood lipids and actually ate more. We now also know that the mice became hypertensive," says Flier.

"This study tells us that increasing this single enzyme in fat cells results in an unexpectedly major impact," he adds. Coupled with findings from the University of Edinburgh showing a correlation between increased enzyme activity in fat tissue and obesity in human subjects, the findings strongly suggest that the 11 beta HSD-1 enzyme is an exciting pharmaceutical target for the treatment of visceral obesity.

"Obesity is a massive problem in our population," says Flier, who has been studying the molecular mechanisms of obesity for the past decade. "It's linked to a huge burden of disease - hypertension, coronary disease, atherosclerosis, cancers, reproductive disorders, diabetes. In fact, an estimated 80 percent of diabetes cases would not exist in the absence of obesity. If we could attack obesity, not only would people feel better, it would also improve all of these other disease states."
Study co-authors include Hiroaki Masuzaki, M.D. and Hiroshi Shinyama, M.D., of Beth Israel Deaconess Medical Center, and Janice Paterson, Nicholas M. Morton, M.D., John J. Mullins, M.D., and Jonathan R. Seckl, M.D., of the University of Edinburgh, Scotland.

This research was funded by the National Institutes of Health (NIH) and Eli Lilly. Beth Israel Deaconess Medical Center is a major patient care, research and teaching affiliate of Harvard Medical School and a founding member of CareGroup Healthcare System. Beth Israel Deaconess is the fourth largest recipient of National Institutes of Health Research funding among independent U.S. teaching hospitals.

Beth Israel Deaconess Medical Center

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to